Published in Int J Med Sci on September 03, 2008
MicroRNA control of bone formation and homeostasis. Nat Rev Endocrinol (2012) 2.05
PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab (2010) 1.77
Genetics of osteoporosis: accelerating pace in gene identification and validation. Hum Genet (2009) 1.14
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood (2009) 1.08
Transcriptomics comparison between porcine adipose and bone marrow mesenchymal stem cells during in vitro osteogenic and adipogenic differentiation. PLoS One (2012) 1.08
A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors. Chem Biol Drug Des (2011) 1.01
Spatial and temporal regulation of gene expression in the mammalian growth plate. Bone (2010) 1.01
miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway. RNA Biol (2015) 0.97
Targeted disruption of ephrin B1 in cells of myeloid lineage increases osteoclast differentiation and bone resorption in mice. PLoS One (2012) 0.96
Bone status in a mouse model of genetic hemochromatosis. Osteoporos Int (2010) 0.95
Eph/ephrin interactions modulate muscle satellite cell motility and patterning. Development (2011) 0.95
Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma (2010) 0.93
Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells. Osteoporos Int (2011) 0.92
Henipavirus receptor usage and tropism. Curr Top Microbiol Immunol (2012) 0.91
The hedgehog pathway conditions the bone microenvironment for osteolytic metastasis of breast cancer. Int J Breast Cancer (2011) 0.91
Pathway-based genome-wide association analysis identified the importance of EphrinA-EphR pathway for femoral neck bone geometry. Bone (2009) 0.90
Alendronate affects osteoblast functions by crosstalk through EphrinB1-EphB. J Dent Res (2011) 0.87
Roles of EphA2 in Development and Disease. Genes (Basel) (2013) 0.86
Hematopoietic cell regulation of osteoblast proliferation and differentiation. Curr Osteoporos Rep (2011) 0.85
Nociceptor-expressed ephrin-B2 regulates inflammatory and neuropathic pain. Mol Pain (2010) 0.85
Netrin-1 is a critical autocrine/paracrine factor for osteoclast differentiation. J Bone Miner Res (2015) 0.83
Ephrin B2/EphB4 mediates the actions of IGF-I signaling in regulating endochondral bone formation. J Bone Miner Res (2014) 0.82
Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov (2016) 0.80
Biomaterial scaffolds for treating osteoporotic bone. Curr Osteoporos Rep (2014) 0.80
microRNA Expression in Rat Apical Periodontitis Bone Lesion. Bone Res (2013) 0.80
Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease. J Clin Invest (2016) 0.78
Compressive force regulates ephrinB2 and EphB4 in osteoblasts and osteoclasts contributing to alveolar bone resorption during experimental tooth movement. Korean J Orthod (2014) 0.78
Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. Oncotarget (2016) 0.77
Bone balance within a cortical BMU: local controls of bone resorption and formation. PLoS One (2012) 0.76
Osteoimmunology and Beyond. Curr Med Chem (2016) 0.75
EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins. Int J Med Sci (2016) 0.75
Cartilage-specific deletion of ephrin-B2 in mice results in early developmental defects and an osteoarthritis-like phenotype during aging in vivo. Arthritis Res Ther (2016) 0.75
Monitoring Cell-surface N-Glycoproteome Dynamics by Quantitative Proteomics Reveals Mechanistic Insights into Macrophage Differentiation. Mol Cell Proteomics (2017) 0.75
Porphyromonas gingivalis lipopolysaccharide regulates ephrin/Eph signalling in human periodontal ligament fibroblasts. J Periodontal Res (2017) 0.75
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell (1997) 16.78
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell (2002) 15.20
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell (1998) 10.61
The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature (1990) 8.94
Genetic regulation of osteoclast development and function. Nat Rev Genet (2003) 7.94
Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol (2005) 7.14
Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol (2002) 6.92
Control of osteoblast function and regulation of bone mass. Nature (2003) 5.06
EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell (2000) 4.34
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab (2006) 4.33
Skeletal remodeling in health and disease. Nat Med (2007) 4.31
Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci (2004) 4.22
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
Cell adhesion molecules: signalling functions at the synapse. Nat Rev Neurosci (2007) 3.47
Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rho-GEF kalirin. Neuron (2003) 3.40
EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res (2001) 3.24
EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell (2001) 3.20
A novel putative tyrosine kinase receptor encoded by the eph gene. Science (1987) 3.10
Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol (2000) 3.09
Wnt-Ryk signalling mediates medial-lateral retinotectal topographic mapping. Nature (2006) 2.92
EphB receptors regulate dendritic spine development via intersectin, Cdc42 and N-WASP. Nat Neurosci (2002) 2.90
Coexpressed EphA receptors and ephrin-A ligands mediate opposing actions on growth cone navigation from distinct membrane domains. Cell (2005) 2.88
Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol (2007) 2.83
Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. Nature (1996) 2.81
EphA-Ephrin-A-mediated beta cell communication regulates insulin secretion from pancreatic islets. Cell (2007) 2.81
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun (1998) 2.66
EphB/syndecan-2 signaling in dendritic spine morphogenesis. Neuron (2001) 2.53
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene (2002) 2.41
Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science (1997) 2.40
Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev (1998) 2.38
The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nature (2001) 2.34
Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature (1997) 2.31
Ephrin-B1 forward and reverse signaling are required during mouse development. Genes Dev (2004) 2.28
Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol (2001) 2.25
Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemoattraction. Cell (2001) 2.20
Control of skeletal patterning by ephrinB1-EphB interactions. Dev Cell (2003) 2.11
Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate (1999) 2.02
Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology (1990) 2.02
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A (2004) 2.01
E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ (1999) 2.01
Mutations of ephrin-B1 (EFNB1), a marker of tissue boundary formation, cause craniofrontonasal syndrome. Proc Natl Acad Sci U S A (2004) 2.01
Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res (2003) 1.98
Modulation of EphA receptor function by coexpressed ephrinA ligands on retinal ganglion cell axons. Neuron (1999) 1.97
EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res (2008) 1.97
Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res (2002) 1.96
Silencing of EphA3 through a cis interaction with ephrinA5. Nat Neurosci (2006) 1.86
Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol (2006) 1.83
Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med (1991) 1.80
Mutations of the ephrin-B1 gene cause craniofrontonasal syndrome. Am J Hum Genet (2004) 1.78
Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J (2006) 1.63
Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J (2005) 1.61
A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene (2005) 1.59
An Eph receptor regulates integrin activity through R-Ras. Proc Natl Acad Sci U S A (1999) 1.57
Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev (1999) 1.52
Eph receptors in the adult brain. Curr Opin Neurobiol (2004) 1.51
Ephrin-B ligands play a dual role in the control of neural crest cell migration. Development (2002) 1.50
EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates paracellular permeability. J Biol Chem (2005) 1.43
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis (2007) 1.41
A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res (1996) 1.40
Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J Cell Sci (2002) 1.38
Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A (1996) 1.37
Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des (2004) 1.33
Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia (2003) 1.30
Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer (1999) 1.28
Parathyroid hormone stimulates bone formation and resorption in organ culture: evidence for a coupling mechanism. Proc Natl Acad Sci U S A (1981) 1.25
The insulin-like growth factor system and the coupling of formation to resorption. Bone (1995) 1.24
Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest (2002) 1.24
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology (2003) 1.24
Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci (2000) 1.22
Phosphorylation of ephrin-B1 via the interaction with claudin following cell-cell contact formation. EMBO J (2005) 1.21
Global gene expression analysis in the bones reveals involvement of several novel genes and pathways in mediating an anabolic response of mechanical loading in mice. J Cell Biochem (2005) 1.18
Eph/ephrin signaling as a potential therapeutic target after central nervous system injury. Curr Pharm Des (2007) 1.13
EphB6-null mutation results in compromised T cell function. J Clin Invest (2004) 1.11
EphB3: an endogenous mediator of adult axonal plasticity and regrowth after CNS injury. J Neurosci (2006) 1.11
EphA and ephrin-A proteins regulate integrin-mediated T lymphocyte interactions. Mol Immunol (2007) 1.11
Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest (2004) 1.07
Recent advances on T-cell regulation by receptor tyrosine kinases. Curr Opin Hematol (2005) 1.05
Identification of the Jak/Stat proteins as novel downstream targets of EphA4 signaling in muscle: implications in the regulation of acetylcholinesterase expression. J Biol Chem (2004) 1.01
A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes. Blood (2000) 1.00
Transforming growth factor-beta and remodeling of bone. J Bone Joint Surg Am (1991) 0.99
Mapping of a further locus for X-linked craniofrontonasal syndrome. Cytogenet Genome Res (2002) 0.94
Expression and function of the Eph A receptors and their ligands ephrins A in the rat thymus. J Immunol (2002) 0.91
Osteoclasts secrete the chemotactic cytokine mim-1. Biochem Biophys Res Commun (2001) 0.90
Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. Pathol Res Pract (2005) 0.86
EphA receptors inhibit anti-CD3-induced apoptosis in thymocytes. J Immunol (2006) 0.86
Ephs and ephrins keep pancreatic Beta cells connected. Cell (2007) 0.80
Bone morphogenetic proteins. Growth Factors (2004) 8.61
E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem (2003) 2.34
Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem (2002) 1.99
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 1.88
Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. J Cell Biol (2002) 1.88
Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res (2006) 1.82
Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J Biol Chem (2003) 1.81
Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol (2011) 1.76
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood (2007) 1.75
Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res (2012) 1.75
Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res (2012) 1.65
The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res (2006) 1.62
Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer (2003) 1.58
Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone (2004) 1.57
TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res (2010) 1.57
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood (2003) 1.56
Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling. J Bone Miner Res (2013) 1.54
Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone (2010) 1.54
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res (2003) 1.52
The pathogenesis of the bone disease of multiple myeloma. Bone (2008) 1.51
Caspase-2 deficiency enhances aging-related traits in mice. Mech Ageing Dev (2006) 1.46
The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. Mol Cell Biol (2006) 1.45
Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer (2010) 1.45
Model structure and control of bone remodeling: a theoretical study. Bone (2008) 1.44
NF-kappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol Chem (2003) 1.35
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood (2004) 1.29
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther (2007) 1.28
Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction. Bone (2010) 1.26
Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells. PLoS One (2012) 1.25
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol (2007) 1.19
The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat (2002) 1.15
Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res (2010) 1.15
Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest (2002) 1.12
Inhibition of microtubule assembly in osteoblasts stimulates bone morphogenetic protein 2 expression and bone formation through transcription factor Gli2. Mol Cell Biol (2008) 1.10
Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS One (2011) 1.08
Quantitative measures of femoral fracture repair in rats derived by micro-computed tomography. J Biomech (2009) 1.05
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. Am J Hematol (2009) 1.05
A murine model of myeloma that allows genetic manipulation of the host microenvironment. Dis Model Mech (2009) 1.04
Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J Bone Miner Res (2011) 1.04
Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One (2010) 1.03
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer (2003) 0.99
Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. J Theor Biol (2009) 0.98
Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res (2009) 0.98
Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. J Bone Miner Res (2010) 0.92
Bmp2 in osteoblasts of periosteum and trabecular bone links bone formation to vascularization and mesenchymal stem cells. J Cell Sci (2013) 0.92
Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. J Bone Miner Res (2010) 0.88
Transdermal lovastatin enhances fracture repair in rats. J Bone Miner Res (2008) 0.85
Advances in the management of myeloma bone disease. Expert Opin Pharmacother (2005) 0.83
Bone metastasis: can osteoclasts be excluded? Nature (2007) 0.81
Bisphosphonates and tumor burden. J Clin Oncol (2002) 0.80
6-Thioguanine inhibition of parathyroid hormone-related protein expression is mediated by GLI2. Anticancer Res (2011) 0.78
New opportunities for the management of cancer-related bone complications. Clin Adv Hematol Oncol (2009) 0.75
In memoriam; Dr. Gideon Rodan. Bone (2006) 0.75
A sustained release of lovastatin from biodegradable, elastomeric polyurethane scaffolds for enhanced bone regeneration. Tissue Eng Part A (2010) 0.75